IDEAYA Biosciences Surges 18% Ahead of Critical Phase 2/3 Melanoma Trial Data Release
IDYA has more than doubled off its 52-week low of $13.45.
Summary
IDEAYA Biosciences announced its plan to release topline results on Monday from its ongoing Phase 2/3 registrational study evaluating darovasertib in combination with crizotinib for a specific type of melanoma. Following this announcement, the company's shares gained 18% in after-hours trading. This news is a significant catalyst for the clinical-stage biotech, as registrational trial results are crucial for potential regulatory approval and commercialization. While the timeline shows recent updates on earlier-stage trials and collaborations, this is the first indication of imminent data from a pivotal study. Traders will be closely monitoring the actual results on Monday, as they will determine the stock's future trajectory.
At the time of this announcement, IDYA was trading at $35.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $13.45 to $39.28. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.